Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?
Viatris Inc.
Viatris Inc (VTRS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 34,168,743 | $542,599,639 | +2% | 4.98% |
| 2. | Deerfield Management James E. Flynn | 20,206,170 | $320,873,980 | 3.35% | |
| 3. | Glenview Capital Larry Robbins | 9,877,409 | $156,853,255 | +9% | 2.86% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 8,371,218 | $132,934,942 | -3% | 0.06% |
| 5. | Callodine Capital Management James Morrow | 8,000,742 | $127,051,783 | -2% | 8.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.43 | 213 | $2,220.63 | 1,183 | 2025-11-03 | Filing | |
| $10.42 | 286 | $2,980.98 | 970 | 2025-08-27 | Filing | |
| $9.99 | 22,000 | $219,740.40 | 314,807 | 2025-08-12 | Filing | |
| $8.94 | 60,000 | $536,262.00 | 292,807 | 2025-05-12 | Filing | |
| $9.01 | 19 | $171.13 | 94,960 | 2023-10-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.17 | 50,076 | $809,784.00 | 316,212 | 2026-06-25 | Filing | |
| $13.28 | 21,350 | $283,538.68 | 366,288 | 2026-03-23 | Filing | |
| $10.25 | 7,032 | $72,044.95 | 35,299 | 2025-09-11 | Filing | |
| $12.88 | 26,925 | $346,686.30 | 126,901 | 2024-11-11 | Filing | |
| $11.66 | 139,681 | $1,628,163.64 | 505,838 | 2024-09-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 96,662,102 | $1,534,994,190 | 0.07% | |
| 2. | 86,019,468 | $1,365,989,163 | 0.02% | |
| 3. | 76,046,939 | $1,207,625,391 | 0.03% | |
| 4. | 75,232,254 | $1,194,789,797 | 5.13% | |
| 5. | 54,282,080 | $861,999,430 | 0.04% |
News See All
Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
The recent breakout of Moderna reminded investors that AI stocks aren't the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely.
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million.
10 Most Undervalued NASDAQ Stocks to Buy Right Now
In this article, we will discuss the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On July 1, Palantir CEO Alex Karp joined CNBC's 'Squawk Box' to discuss Palantir's deal with NVIDIA.
Top 10 Extreme Value Stocks To Buy Now
In this article, we will look at the Top 10 Extreme Value Stocks To Buy Now.
Viatris Inc. (NASDAQ:VTRS) Q1 2026 Earnings Call Transcript
Viatris Inc. (NASDAQ:VTRS) Q1 2026 Earnings Call Transcript May 7, 2026Viatris Inc. beats earnings expectations. Reported EPS is $0.59, expectations were $0.52.
10 Best Medical Stocks to Buy Under $30
In this article, we will be looking at the 10 Best Medical Stocks to Buy Under $30.
10 Best Stocks Under $20 to Buy According to Hedge Funds
In this article, we will be looking at the 10 Best Stocks under $20 to Buy According to Hedge Funds.
Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value
Viatris Inc. (NASDAQ:VTRS) is one of the dirt cheap stocks to buy now.
12 Dirt Cheap Stocks to Buy Now
On February 23, Pierre Ouimet, head investment strategist at UBS Canada, joined BNN Bloomberg to discuss the markets and provide a spotlight on undervalued sectors.
Hedge Fund Resource Center